BeCytes Biotechnologies

BeCytes Biotechnologies, founded in 2018 and based in Barcelona, Spain, is a specialized provider of primary liver cells and tissue procurement services for the global research community. Its core business model combines the sale of cellular products with a preclinical CRO division, offering scientific guidance and validation services. The company's recent acquisition by BioIVT provides it with enhanced scale, resources, and international distribution channels, positioning it as a key player in the research tools and services sector for liver disease and toxicology studies.

Platform for tissue procurement, isolation, and culture of primary liver cells (human and animal). Offers fresh, cryopreserved, and plateable hepatocytes. Provides a coordinated network for human tissue sourcing and a suite of preclinical CRO services (cell culture, molecular biology, imaging, etc.). Involved in Organ-on-Chip (OOC) technology development via the UNLOOC consortium.

BeCytes competes in the niche market for primary liver cells and specialized hepatic research services against other primary cell providers and preclinical CROs. Its key differentiator is deep expertise in hepatology and a dedicated tissue sourcing network. Post-acquisition, its primary competition includes other global research model providers like Charles River Laboratories, Lonza, and STEMCELL Technologies, though it now benefits from BioIVT's established market position.